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Even though cannabis’ federal status remains under Schedule I categorization the 
legality of recreational marijuana is rapidly changing across the United States. As of 
March 2021, sixteen states plus Washington, D.C. have legalized cannabis’ recreational 
use and dispensaries (DISA Global Solutions, 2021). Considerable controversy follows 
this trend in drug legalization, specifically regarding its public health impact on children.  
As states continue to proceed with the decriminalization and legalization of 
cannabis, those in the public health field are concerned with how this will impact children 
across the country, as historically, “adolescents and young adults are among the highest 
users of marijuana” (Ladegard et al., 2020). A comprehensive review on cannabis, 
focusing on both its history and legal landscape in the United States will be presented. 
Additionally, cannabis’ use in pediatric and adolescent cases will be analyzed to 
determine the trajectory of cannabis use for these patients. Ultimately, this paper will 
investigate if medical cannabis utilization in pediatric and adolescent populations 
potentiates the need for these patients to use cannabis in the future, especially if it is 
recreationally legal.  
After much research it is reasoned that medicinal cannabis should continue to be 
an alternative treatment option for those pediatric and adolescent cases in which normal 
treatments are ineffective. However, more research is needed to investigate the potential 






Medicinal Legal Landscape 
The United States’ relationship with cannabis dates back to the 17th Century 
where the production of hemp, the cannabis plant, was encouraged by the government 
(Marijuana Timeline, 1998). Hemp was used for the production of a broad variety of 
products from rope to clothing and was even considered a proper form of currency in 
Maryland, Pennsylvania, and Virginia (McNearney, 2018). Nonetheless, domestic 
production of hemp faded quickly and was gone by the end of the Civil War. Although 
hemp was no longer popular, a different version of the plant, marijuana – with a high 
quantity of hallucinogenic agent THC, became mainstream. In the, “late 19th Century, 
marijuana became a popular ingredient in many medicinal products and was sold openly 
in pharmacies” (McNearney, 2018). Drug producers like Eli Lily, added marijuana to 
analgesics, antispasmodics, and sedatives (Braun, 2019).  
The acceptance of marijuana both medicinally and recreationally changed 
throughout the next century. The Mexican Revolution of 1910 influenced American’s to 
associate cannabis with anti-immigration sentiment and fear. This fear grew throughout 
The Great Depression and by 1931, twenty-nine states had completely outlawed cannabis 
(Marijuana Timeline, 1998). Following this trend, in 1937 the federal government 
effectively taxed and criminalized both medical and non-medical forms of marijuana 
through the Marihuana Tax Act (Braun, 2019). It is important to note here that the 
American Medical Association (AMA) opposed this act and actively lobbied against it, 




drug use” (Marijuana Timeline, 1998). Medicine firmly disagreed with government 
policy, believing cannabis was safe and needed to be researched. This concept continues 
to create tension today. 
In the following decades, even with the cultural shift of the 1960s and a “renewed 
interest in the medical properties of cannabis,” (Mead, 2019) the persistent negative 
attitude about marijuana was not derailed. In 1970, Congress enacted the Controlled 
Substances Act, which is still in affect today (Braun, 2019). This act consolidates all 
previous federal laws governing the handling of hallucinogens, narcotics, and other drugs 
and classifies these substances into 5 distinct categories or schedules. These schedules are 
dependent on the drug’s medical use and abuse or dependency potential. When enacted, 
and currently at this time, cannabis’ federal status is under the most harsh Schedule I 
categorization. It is seen as a drug with, “no current acceptable medical use and a high 
potential for abuse” (Drug Enforcement Administration [DEA], n.d). The Schedule I 
designation has created challenges in accessing federal funding for medical cannabis 
studies, sourcing cannabis as a study drug, and even creates significant issues with 
personal, financial, and criminal liability of study participants and study centers.  
Following the Controlled Substances Act, the United States enacted a War on 
Drugs, which lasted until the mid 1990s. In this campaign mandatory sentences were re-
enacted for drug related crimes and life sentences were demanded for repeat drug 
(cannabis) offenders (Marijuana Timeline, 1998). This crusade was harsh, but “ended” in 
1996 as California passed proposition 215, “allowing for the sale and medical use of 







More recently, there has been a major shift in the United States’ perception. 
Medical cannabis is comprehensively used throughout most of the country. As of March 
2021, twenty-seven states have fully decriminalized and legalized medicinal cannabis, 
with fourteen more allowing limited medical use (DISA Global Solutions, 2021). In 
comparison there are only three states in which medical cannabis is fully illegal and 
criminalized.  
In states where medical marijuana is legal, individuals over the age of twenty-one 
with a qualifying condition can obtain this substance. Such people must seek consent 
from a physician as well as join their state’s medicinal marijuana registry. In addition, 
minors, those under eighteen years of age, are also able to access medical marijuana with 
consent from a legal guardian and certification from a physician (National Conference of 
State Legislatures [NCSL], 2021). Many states however, “require a second physician for 
the certification of a minor’s use… including four states that require specific certification 
from a pediatrician, or pediatric subspecialist, or pediatrician and psychiatrist” (Wong & 
Wilens, 2017).  
In addition to the acceptance of medical cannabis, the United States has been 
becoming more progressive towards recreational usage; sixteen states as of March 2021 
have fully legalized recreational cannabis. Under these states’ legislation, adults over the 
age of twenty-one may posses and use any form of cannabis. Those under twenty-one, if 




Pediatrics, opposes dispensing medical cannabis to children and adolescents outside the 
regulatory process of the US FDA. Although, the Academy does recognize that cannabis 
may currently be an option for ‘certain unique situations’ for children with life-limiting 
or severely debilitating conditions and for whom current therapies are inadequate. (Wong 
& Wilens, 2017) 
Cannabis Role in Pediatric and Adolescent Populations 
Interests in the medical applications of cannabis have increased dramatically 
during the past twenty years. The Food and Drug Administration (FDA) currently 
approves of two cannabinoids in the United States, Dronabinol (Marinol) and Nabilone 
(Cesamet), both of which are only available by physician prescription (Wong & Wilens, 
2017). These drugs in both pediatric and adolescent cases are used to treat chemotherapy-
induced nausea and vomiting, epilepsy, spasticity, and neuropathic pain.  
When preventing or treating acute chemotherapy-induced nausea and vomiting in 
pediatric or adolescent patients, physicians commonly have adopted, “the ‘triple therapy’ 
regimen of antiemetic prophylaxis” (Sherani et al., 2019). This therapy includes usage of 
a 5-HT3 antagonist, dexamethasone, and a neurokinin-1 antagonist, all of which have 
little to no adverse side effects when given in the correct dosage (Sherani et al., 2019). 
The alternative treatment of medical cannabis is used for patients who have failed to 
respond adequately to conventional antiemetic therapy (Campbell et al., 2017). In 
previous studies Dronabinol and Nabilone have decreased nausea severity, frequency, 




cause for concern is when given in too high of a dosage Dronabinol and Nabilone can 
have the reverse effect, causing hyperemesis.  
 The most common use of Dronabinol and Nabilone is in treating drug-resistant 
epilepsy, seizures not controlled by anticonvulsant medications. Devinsky et al. (2017) 
found that cannabinoid treatment for children with Dravet Syndrome, early onset 
epilepsy, significantly reduced convulsive seizure frequency as compared to placebo. In 
addition, further research has proven that medical cannabis is useful to treat other 
syndromes. Gofshteyn et al. (2016) and Kaplan et al. (2017) report reduction of seizures 
in patients with febrile infection related epilepsy syndrome (FIRES) and Sturge-Weber 
syndrome, respectively.  
 Spasticity and neuropathic pain in pediatric and adolescent cases are also 
alternatively treated with the cannabinoids. Even though studies are scare and those that 
are available, like Kuhlen et al. (2016), have a risk of bias because of a lack of controls 
and blinding, results are in alignment with adult literature findings. Evidence suggests 
that patient reported pain and spasticity symptoms are improved with oral cannabinoids. 
(Wong & Wilens, 2017). 
 Although there is substantial evidence that medical cannabis provides potential 
health benefits for pediatric and adolescent populations, as discussed above, pediatricians 
and parents must weigh the benefits of cannabis use with its potential risks before 
consenting to allow their patients or children to use this substance. 
 The negative side effects of medical cannabis have been well documented. In the 




drowsiness and dizziness, diarrhea, and decreased appetite ( Wong & Wilens, 2017). 
Although not pleasant, when compared to the potential side effects of anticonvulsant or 
pain drugs for children they are minimal. All of these side effects occurred at high 
dosages, and when dosages were reduced minimal to no side effects were reported. It is 
important to note, serious short-term side effects due to the accidental overdose of 
medicinal cannabis are hyperemesis and seizures. 
 Studies concerning the long-term risks of medical cannabis to pediatric and 
adolescent populations are absent. However, as potential long-term risks can directly 
influence pediatricians and parents in the decision to prescribe or seek the use of medical 
cannabis, it is important to try and extrapolate adverse effects using data collected about 
recreational marijuana. 
 During adolescence (11 to 21 years old) a child’s brain is constantly growing and 
developing, therefore it is vulnerable to alterations from substances such as recreational 
marijuana or medical cannabis. Recent research suggests that, “individuals who begin 
using cannabis regularly in adolescence tend to have different cortical and subcortical 
volumes… that can correlate to cognitive impairments such as attention deficits, verbal 
memory deficits, and behavioral changes” (Wong & Wilens, 2017). Furthermore, 
recreational cannabis use in adolescence has been linked to earlier onset and higher rates 
of psychosis in susceptible patients (Ammerman et al. 2015). Bechtold et al. (2016) 
supports this theory by concluding that adolescent cannabis use leads to high levels of 
psychotic symptoms like paranoia despite one year of abstinence. Although there are 




dosing, and potency” (Wong & Wilens, 2017), it is important to use all data at hand to 
theorize the potential long-terms effects for pediatric and adolescent medical cannabis 
users. 
Impact of Cannabis Policies on Pediatric and Adolescent Populations  
 As states continue to proceed with the decriminalization and legalization of both 
medicinal and recreational cannabis, it is of increasing concern how this can impact 
pediatric and adolescent children. In 2015, a technical report by Ammerman et al. was 
released through The American Academy of Pediatrics and analyzed data from recent 
studies as well as national databases, Monitoring the Future (MTF) and the National 
Survey of Drug Use and Health, to report on the impact changing cannabis legality has 
had. Ammerman et al (2015) state that, when all high school data are combined for each 
state in which medical marijuana is legalized and for which data for current use before 
and after medical marijuana legalization are available (14 states to date), no state with 
legalized medical marijuana has shown a statistically significant increase in adolescent 
recreational marijuana use except Delaware; 2 states (Alaska and Montana) have shown 
statistically significant decreases.  
Is this enough proof that legalizing and allowing the use of medical cannabis will not 
affect children? Or is it too early to tell?  
In addition to these findings, Ammerman et al (2015) established that, “states with 
legalized medical marijuana reported lower rates of perception of riskiness of marijuana 




the verge of another crisis like we have experienced with prescription pain relievers? 




 A review of the literature on medical cannabis use in pediatric and adolescent 
populations was preformed using Google Scholar, PubMed, P.C.O.M’s OneSearch+, and 
the Journal of the American Academy of Pediatrics. The following search terms were 
used: (“cannabis” or “cannabinoid” or “marijuana” or “medical marijuana”) AND 
(“pediatric” or “adolescent” or “youth.”) Articles published from 2015 to 2020 were 
prioritized and included if they pertained to one of the following: conditions for treatment 
with medical cannabis, efficacy of medical cannabis for certain conditions, short- or long-
term effects of medical cannabis, and any other characteristics describing cannabis’ 
reactions in pediatric or adolescent populations. Only studies or systemic reviews on 













Trajectory of Cannabis Use for Pediatric and Adolescent Populations 
Medical cannabis remains a controversial topic, especially in regards to pediatric 
and adolescent cases. As it is used as an alternative therapy to treat chemotherapy-
induced nausea and vomiting, epilepsy, spasticity, and neuropathic pain one can conclude 
that it is medically relevant. However, it is neither devoid of potentially harmful effects 
nor universally effective. So the question remains should cannabis continue to be used as 
a treatment for young patients?  
To answer this question one must consider the impact medical cannabis’ side 
effects can have on the quality of a child or adolescents’ life. The short-term adverse 
reactions of drowsiness and fatigue, diarrhea, and decreased appetite are not severe. They 
are unpleasant and may hinder users from doing certain tasks, such as driving or playing 
intensive sports, but they do not further handicap. Cannabis’ mild short-term effects 
instead permit children and adolescents to acquire or maintain a normal life. Normalcy, 
especially among children and adolescents can have a major impact on their health equal 
to that of any drug treatment. When youth, especially those with long term illnesses, are 
able to participate in every-day age appropriate activities and are not hindered by adverse 
reactions to drug treatments amazing things occur. They are able to learn skills and 
develop relationships that promote social well-being and healthy development. For 




a way to be normal and gain back control. The short-term adverse effects can be 
overlooked due to such a positive impact. 
The long-term effects of medical cannabis have yet to be studied. It is unknown 
how Dronabinol and Nabilone can effect brain development and long-term growth in 
children and young adults. As previously mentioned, data on the long-term effects of 
recreational marijuana is readily available and has been used to extrapolate medical 
cannabis’ long-term effects. The potential long-term adverse reactions of cognitive 
impairment, behavioral challenges, and early onset psychosis negatively impact a child’s 
life. It would be extremely difficult to achieve normalcy or even develop appropriate 
skills needed in adulthood with any of these potential long-term reactions. However, as 
medicinal and recreation cannabis are different the conclusions extrapolated from 
recreational cannabis studies are not representative of medical cannabis’ potential effects. 
Before one can support normalizing the use of medicinal cannabis in adolescent and 
pediatric populations, questions regarding cannabis’ long lasting impact must be 
answered. 
Thus, the simple answer to if cannabis should continue to be used as a treatment 
for young patients is yes. Medicinal cannabis should continue to be an alternative 
treatment option for those pediatric and adolescent cases in which normal treatments are 
ineffective. However, more research is needed to investigate any potential long-term 
effects medicinal cannabis can have before accepting it as a normal treatment option. 




well as parents can not make informed decisions on whether or not to allow this treatment 
path. 
Trajectory of Cannabis Impact on Pediatric and Adolescent Populations 
As states continue to proceed with the decriminalization and legalization of both 
medicinal and recreational cannabis it is important to discuss the impact this changing 
legal landscape can have on pediatric and adolescent children. Described earlier, data 
from nation wide sources revealed that adolescent recreational marijuana usage did not 
significantly increase when a state legalized medical cannabis (Ammerman et al., 2015). 
This illustrates an interesting point. The legalization of medical cannabis does not have 
an impact on adolescent recreational usage. This conclusion was drawn by monitoring 
states over a short time period following each states’ medicinal cannabis legalization, so 
longer-term results may indicate a different trend. Nevertheless, this supports the idea 
that medical cannabis has more of a positive impact then it does negative on pediatric and 
adolescent populations. In light of this relationship one must consider if the legality of 
recreational cannabis could influence the use of medical cannabis. Does recreational 
legalization have a positive or negative impact, on adolescent medical cannabis use? 
Technically, legalizing recreational cannabis allows adolescents greater ease of access to 
all types of cannabis and cannabinoids, which could potentially influence negative 
substance use. So would a child, who is currently being prescribed a cannabinoid as a 
treatment for a disease, prefer to use recreational cannabis and “self-prescribe” if legal? 




With the legalization process predicted to continue, the question of nationwide 
marijuana legalization is more a matter of when, not if. So how can the United States 
properly introduce cannabis to limit its impact on youth? First, states that are considering 
allowing recreational cannabis or those that already allow it should conservatively 
regulate its sale through strict laws. It may be beneficial to introduce laws that mimic 
those of tobacco and alcohol that limit where cannabis can be sold, who can sell it, and 
increase the age needed to purchase this substance. These laws influence those in 
adolescent populations and dissuade many from trying to obtain cannabis. Next, public 
health campaigns that effectively describe the harm and negative side effects associated 
with adolescent cannabis use are needed. They would discourage the population from 
trying or continuing use of cannabis even despite cannabis being legal. Simply, such 
campaigns would influence adolescents’ to perceive cannabis as harmful and encourage 
them to cease trying it. A good model to use to produce cannabis’ public health 
campaigns would be tobacco’s “The Real Cost” campaign (Food and Drug 
Administration, 2021) as tobacco is marketed and sold much like recreational cannabis. 
Lastly, those in the medical and public health fields must discourage the use of marijuana 
by adults in the presence of children and adolescents. Role modeling healthy behaviors is 
key to influencing children and adolescents. By following these three suggestions the 









After presenting a comprehensive review on cannabis, focusing on its history, 
legal landscape, and use in pediatric and adolescent populations there are many directions 
in which further research is needed. The first being that studies should investigate the 
long-term effects of medicinal cannabis in pediatric and adolescent patient populations. 
This data is needed so physicians and parents can make better-informed decisions about 
using cannabis as an alternative treatment option. Extrapolating medicinal cannabis’ 
effects from studies on recreational cannabis is not sufficient enough. Other research 
should be directed toward analyzing how the changing legal landscape of cannabis is 
impacting youth across the nation. Researchers should look to firmly answer the question, 
if legalizing either medicinal or recreational cannabis influences youth cannabis use 
rates? Additionally, it is important to examine what, if any, impact does legalization have 
on children already using medical cannabis? With the question of nationwide marijuana 
legalization more a matter of when, not if it, is important that more research is done on 
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